25
OCT
2011

Northwest Bio Announces Initiation Of S&P Coverage, With Publication Of First Company Stock Report

Posted By :
Comments : Off
To Be Made Available To 100,000 Participating Investment Advisors BETHESDA, MD, October 25, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced initiation of Factual Stock Report coverage in conjunct- ion with Standard & Poor’s Market Access Program, an information distribution service that enables subscribing publicly traded companies to have corporate information disseminated to users of...
Read More
06
OCT
2011

Northwest Bio Announces Positive Third Quarter Progress

Posted By :
Comments : Off
Exceeds Projections, With 17 Active Clinical Trial Sites S&P To Initiate Coverage BETHESDA, MD, October 6, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it has exceeded its Q3 projection of 15 clinical trial sites by the end of the quarter, with 17 sites at major medical institutions across the U.S. now open and active where patients can enroll in the Company’s ongoing clinical trial o...
Read More
04
OCT
2011

Northwest Bio Will Present At The Second Annual “Cancer Immunotherapy: A Long Awaited Reality Conference” At The New York Academy Of Medicine, October 6, 2011

Posted By :
Comments : Off
Timely Conference, Following Yesterday’s Announcement Of Nobel Prize Presentation Will Be Broadcast Live On the Web BETHESDA, MD, October 4, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) (NORTHWEST BIO) today announced that it will be presenting at the second annual Cancer Immunotherapy: A Long-Awaited Reality Conference on Thursday, October 6, at the New York Academy of Medicine in New York City. The single-day conference...
Read More
10
AUG
2011

NWBT Highlights Cost Effectiveness Of DCVax® In View Of Recent Immunotherapy Pricing Concerns

Posted By :
Comments : Off
Bethesda, Maryland, August 10, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) reminded markets, in response to recent investor concerns about Dendreon’s Provenge immune therapy, that NWBT’s DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing...
Read More
04
AUG
2011

NWBT Announces Further Expansion Of Clinical Sites In Ongoing Brain Cancer Trial

Posted By :
Comments : Off
Bethesda, Maryland, August 4, 2011 — Northwest Biotherapeutics (OTC.BB: NWBO) today announced that it has expanded its number of clinical trial sites, and now has 12 sites across the U.S. open and active, where patients can enroll in the Company’s ongoing clinical trial of DCVax®immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. The Company also announced that a substantial number of additional...
Read More